The BioCentury Show

BioCentury Podcasts
  • 0.0（0）
  • 生命科学
  • アップデート：隔週

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

  1. Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development

    6日前

    Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development

    Caution: This episode of The BioCentury Show contains strong language. In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slowing drug development and pushing companies to launch early-stage trials outside the U.S. In conversation with BioCentury Washington Editor Steve Usdin, Kolchinsky also discusses U.S. policy headwinds, including most-favored-nation (MFN) pricing proposals and the Inflation Reduction Act’s “pill penalty,” and why he’s concerned that the biopharma sector is too “genteel” in its advocacy. Kolchinsky explains his decision to speak publicly about regulatory and political issues, including immigration, and reflected on China’s expanding role in the global life sciences innovation ecosystem. View full story: https://www.biocentury.com/article/658433 #BiotechPolicy #FDALeadership #DrugPricingPolicy #LifeSciencesInnovation #CapitalMarkets 00:00 - Introduction 00:37 - Impact of FDA Policy Changes 06:17 - MFN & Drug Pricing in Europe 20:16 - The Importance of Speaking Up 34:26 - China & Innovation

    41分
  2. Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs

    2月6日

    Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs

    With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypotheses into usable medicines, says veteran CNS drug developer Steven Paul. Few drug developers have had a closer view of the field’s false starts — and occasional breakthroughs — than Paul, who has moved from NIH to pharma R&D leadership and now to company building at Karuna, acquired by BMS for $14 billion, and Seaport. In conversation with The BioCentury Show's Selina Koch, Paul explains why serendipity still plays a disproportionate role in psychiatric drug development and how critical it is for teams to engineer and execute their way from an unexpected signal to a usable medicine. He also discusses psychedelics, brain shuttles, Karuna’s muscarinic approach in schizophrenia, and the delivery and trial-design choices Seaport is using to revisit neuroactive steroid biology in depression. View full story: https://www.biocentury.com/article/658314 #PsychiatryTherapeutics #CNSDrugDevelopment #BiotechEngineering #Psychedelics #NeuroScience 00:00 - Introduction 01:32 - Psychiatric Drug Discovery 06:56 - The Karuna Story 22:09 - What’s New in Depression 32:06 - Gene Therapies, Brain Shuttles 33:53 - Psychedelics

    41分
  3. Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms

    1月23日

    Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms

    Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move ideas across the boundaries of biology, manufacturing, regulation and commercialization. That theme threaded through his conversation on The BioCentury Show with Executive Editor Selina Koch, surfacing most clearly in his diagnosis of what Japan’s biotech ecosystem lacks — and in his rationale for why Astellas is doubling down on cell and gene therapy as other multinational pharmas pull back. The discussion also touches on Astellas’ journey in commercializing a women’s health product, the company’s China strategy, and its plans for life after Xtandi’s patent cliff. View full story: https://www.biocentury.com/article/658141 #BiotechTranslation #CellAndGeneTherapy #JapanBiotech #PharmaStrategy #DrugDevelopment 00:00 - Introduction 00:39 - Cell & Gene Therapy 07:22 - Women’s Health 13:00 - Japan’s Biotech Ecosystem 19:00 - Astellas’ China Strategy 22:45 - Astellas’ Near-Term Strategy

    29分
  4. Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next

    1月9日

    Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next

    Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to conduct the technical diligence required for investments once considered too risky for their models. In conversation with The BioCentury Show's Stephen Hansen, Bain Capital’s Adam Koppel discussed the evolution of private equity's interest in biotech, Bain’s prioritization scheme for scaled investments and his outlook for the capital markets in the year ahead. View full story: https://www.biocentury.com/article/657997 #PrivateEquity #BiotechDeals #LifeSciencesInvesting #GrowthEquity #BiopharmaMarkets 00:00 - Introduction 01:57 - PE's Evolution in Biotech 06:58 - Bain's Priorities 11:24 - Structuring Deals 18:23 - Capital Market Conditions 24:03 - Environment for Private Companies 27:08 - IPO Outlook

    37分
  5. Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma

    2025/12/19

    Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma

    In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary science, the likes of which we’ve never seen — and it’s getting better,” said Papadopoulos on The BioCentury Show. Papadopoulos is one of the long-term leading voices of biopharma, recognized for his influence in shaping the industry. Former chair of Biogen and current chair of Exelixis, with roles on several boards, and a background of nearly two decades as an investment banker, he brings a long view to how the industry has grown and the forces driving where it is headed. Tune in to hear his take on the financing environment for biotechs, company building, pricing pressure, innovation from China, and the future of big pharmas, in conversation with Editor in Chief Simone Fishburn. View full story: https://www.biocentury.com/article/657910 #BiotechOutlook #DrugPricing #ChinaBiotech #BigPharma #BiopharmaStrategy 00:00 - Introduction 02:00 - Financing Environment 10:18 - Company Building 20:47 - Women in Biotech 25:38 - China, Korea & Europe 30:00 - Is Biotech Too Insular?

    38分
  6. Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw

    2025/12/05

    Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw

    When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by technological ambition, yet still grappling with many of the structural challenges that defined its beginnings, now compounded by the difficulty of positioning therapies within an ever more complex treatment landscape. Gleevec proved the power of targeting a genomic driver, but the healthcare system around it was far from ready. “We weren’t able to fulfill the promise as fast as we wanted to until that scaling happened,” Hinshaw told The BioCentury Show — a reminder that even today, precision medicines succeed or fail based not only on their biology but on the infrastructure that enables patients to access them. Hinshaw sat down with Executive Editor Selina Koch on The BioCentury Show to discuss what’s changed in precision oncology, what’s stayed the same, and how he’s applying those lessons to steer Fore’s BRAF-focused program. View full story: https://www.biocentury.com/article/657768 #PrecisionOncology #BRAFAlterations #NGSTesting #MasterProtocol #TargetedTherapies 00:00 – Introduction 00:47 – Precision Medicine’s Evolution 09:22 – Zeroing in on Subtypes 17:59 – Fore’s BRAF Inhibitor 26:38 – Fore’s Development Approach 32:01 – Moving from Pharma to Biotech

    38分
  7. Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future

    2025/11/27

    Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future

    This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Back to School essay, authored by BioCentury Washington Editor Steve Usdin, who has been a leading voice on regulation and policy for over two decades. The topic is especially meaningful in this era of FDA turmoil, when regulatory risk has piled on top of the market pullback, making biotech appear an unusually hazardous domain for investors. But while the current landscape has underscored the need, FDA reform has been on the table long before this administration came into power. On this edition of The BioCentury Show, Usdin and Editor in Chief Simone Fishburn discuss the key arguments, and some specific concepts, within Back To School, which reimagines the U.S. drugs regulator. View full story: https://www.biocentury.com/article/656928 #FDA #DrugRegulation #Biopharma #LifeSciences #Biotech #PublicTrust 00:00 - Introduction 02:39 - Restructuring FDA 18:08 - A Learning Regulatory Agency 27:54 - Global View 31:09 - Talent 32:59 - User Fees

    39分
  8. Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science

    2025/11/14

    Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science

    Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic career. In 2002, he was nominated and confirmed as NIH director, and later he served in senior positions in the biopharma industry. That trajectory “would be almost impossible” today, he told BioCentury Washington Editor Steve Usdin on The BioCentury Show. Anti-immigration policies, underfunding of basic research, and attacks on philanthropy have made the U.S. an unattractive destination for anyone hoping to follow his path, Zerhouni said. Zerhouni also discussed reasons for optimism about life sciences in the U.S., the difficulty of fixing drug pricing, and his time at Sanofi. View full story: https://www.biocentury.com/article/657591 #NIH #BiomedicalInnovation #ImmigrationPolicy #Biopharma #LifeSciences #HealthcareReform #MedicalResearch 01:09 - The American Dream & Science 05:51 - Zerhouni at NIH 09:40 - Loss of Trust 16:53 - Vaccine Policy 20:12 - Zerhouni in Industry 23:20 - Drug Pricing

    34分
すべて見る（55）

番組について

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

情報

  • チャンネル
    BioCentury Podcasts
  • クリエイター
    BioCentury
  • 配信期間
    24年 - 26年
  • エピソード
    55
  • 制限指定
    不適切な内容を含む
  • Copyright
    © 2026 BioCentury Inc. All Rights Reserved.
  • 番組のWebサイト
    The BioCentury Show

BioCentury Podcastsの他の作品

その他のおすすめ